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Abstract
Sporadic Creutzfeldt-Jakob-disease (sCJD) is a fatal neurodegenerative condition that escapes detection until autopsy.
Recently, brain iron dyshomeostasis accompanied by increased transferrin (Tf) was reported in sCJD cases. The consequence
of this abnormality on cerebrospinal-fluid (CSF) levels of Tf is uncertain. We evaluated the accuracy of CSF Tf, a ‘new’
biomarker, as a pre-mortem diagnostic test for sCJD when used alone or in combination with the ‘current’ biomarker total-
tau (T-tau). Levels of total-Tf (T-Tf), isoforms of Tf (Tf-1 and Tf-b2), and iron saturation of Tf were quantified in CSF collected
0.3–36 months before death (duration) from 99 autopsy confirmed sCJD (CJD+) and 75 confirmed cases of dementia of non-
CJD origin (CJD-). Diagnostic accuracy was estimated by non-parametric tests, logistic regression, and receiver operating
characteristic (ROC) analysis. Area under the ROC curve (AUC), sensitivity, specificity, positive and negative predictive values
(PV), and likelihood ratios (LR) of each biomarker and biomarker combination were calculated. We report that relative to
CJD-, CJD+ cases had lower median CSF T-Tf (125,7093 vs. 217,7893) and higher T-tau (11530 vs. 1266) values. AUC was 0.90
(95% confidence interval (CI), 0.85–0.94) for T-Tf, and 0.93 (95% CI, 0.89–0.97) for T-Tf combined with T-tau. With cut-offs
defined to achieve a sensitivity of ,85%, T-Tf identified CJD+ cases with a specificity of 71.6% (95% CI, 59.1–81.7), positive
LR of 3.0 (95% CI, 2.1–4.5), negative LR of 0.2 (95% CI, 0.1–0.3), and accuracy of 80.1%. The effect of patient age and duration
was insignificant. T-Tf combined with T-tau identified CJD+ with improved specificity of 87.5% (95%CI, 76.3–94.1), positive
LR of 6.8 (95% CI, 3.5–13.1), negative LR of 0.2 (95% CI, 0.1–0.3), positive-PV of 91.0%, negative-PV of 80.0%, and accuracy of
86.2%. Thus, CSF T-Tf, a new biomarker, when combined with the current biomarker T-tau, is a reliable pre-mortem
diagnostic test for sCJD.
Citation: Singh A, Beveridge 9AJ, Singh N (2011) Decreased CSF Transferrin in sCJD: A Potential Pre-Mortem Diagnostic Test for Prion Disorders. PLoS ONE 6(3):
e16804. doi:10.1371/journal.pone.0016804
Editor: Jiyan Ma, Ohio State University, United States of America
Received September 24, 2010; Accepted December 31, 2010; Published March 9, 2011
Copyright:  2011 Singh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funds from National Institutes of Health grant R21AG109106 to NS. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: neena.singh@case.edu
. These authors contributed equally to this work.
Introduction
Sporadic Creutzfeldt-Jakob disease is a uniformly fatal prion
disorder of humans that results from refolding of the normal prion
protein (PrP
C)toab-sheet richpathogenicconformationcalledPrP-
scrapie(PrP
Sc) [1,2].Currently,the only definitive diagnostic test for
sCJD is based on detection of PrP
Sc in the brain tissue obtained by
biopsy or at autopsy [2]. Available pre-mortem diagnostic tests have
provided inconsistent results, making it difficult to use therapeutic
options where available [3–8]. Moreover, undiagnosed cases of
sCJD are likely to transmit the disease to healthy individuals, raising
significant public health concerns [2,9].
Consequently, significant effort has gone into the identification of
sensitive and specific biomarkers for sCJD [8,10,11]. Of these,
analysis of CSF proteins has proved promising due to its reasonable
reliability and low cost. Commonly tested CSF proteins include 14-
3-3, total tau (T-tau), S100B, and neuron-specific enolase (NSE)
[12–17]. Several large scale studies, some across centers, have
exploredtheaccuracyofthesebiomarkersinthe contextofvariables
suchasclinicalstage ofdisease,valine/methionine polymorphismin
the prion protein gene, and sub-type of sCJD [18–23]. Based on
these and other considerations, the World Health Organization
approved a combination of CSF 14-3-3 and EEG for the pre-
mortem diagnosis of clinically suspected cases of sCJD [12,23,24].
Subsequent studies reported high sensitivity but relatively low
specificity of this test, resulting in its replacement by a combination
of CSF 14-3-3 and T-tau for cases of dementia suspected of sCJD
[3–6,14,17,25]. However, subsequent reports indicated varying
sensitivity and specificity for 14-3-3 and T-tau when used singly or
in combination, re-kindling the debate and dissent concerning the
diagnostic accuracy of this test [3–6,14,17,27–31].
Major factors contributing to the inconsistent performance of 14-3-
3 and T-tau combination include: 1) variable false positives since 14-
3-3 and T-tau are elevated in several other dementias besides sCJD
[29–31],2)experimentalvariabilityof14-3-3thatissemi-quantitative
at best [4–6], and 3) lack of comparative analysis of biomarker
accuracy within and across studies using a rigorous statistical
approach [12–23]. To address these weaknesses, it is critical to
identify a biomarker that is altered by sCJD associated pathology and
therefore specific, abundant in the CSF and easily quantifiable, and
superior in diagnostic accuracy relative to the current biomarkers 14-
3-3 and T-tau using uniform benchmarks of analysis.
One such potential biomarker is Tf that is increased in sCJD
and prion disease affected animal brains [32–36]. The effect of this
PLoS ONE | www.plosone.org 1 March 2011 | Volume 6 | Issue 3 | e16804change on CSF levels of Tf, however, is not known. In this study,
we analyzed levels of CSF Tf in 99 autopsy confirmed cases of
sCJD (CJD+) and 75 cases of dementia of non-CJD origin (CJD-)
to evaluate the potential of CSF Tf and its isoforms Tf-1 and Tf-b2
as ‘new’ diagnostic biomarkers of sCJD. The diagnostic accuracy
of new biomarkers was compared with the ‘current’ biomarker T-
tau using common standards of evaluation and rigorous statistical
modeling. Finally, the diagnostic accuracy of optimal ‘new’
biomarker and T-tau combination was compared with the 14-3-
3 and T-tau combination currently used for the pre-mortem
diagnosis of sCJD.
Methods
Ethics statement
Human tissue and CSF samples were obtained from the
National Prion Disease Pathology Surveillance Center (NPDPSC)
at Case Western Reserve University, Ohio. All samples are from
deceased subjects, and personal information is limited to age, sex,
symptoms, neuropathology, and classification of prion disease.
The use of these samples has been granted waiver of informed
consent by the Case Western Reserve University Institutional
Review Board since the protocol meets criteria for exemption
under Federal regulations 45 CFR 46.101 (b).
Human samples. To avoid sample bias, pre-mortem CSF
from autopsy-confirmed cases of sCJD (CJD+) and dementia of
non-CJD origin (CJD-) received between 2006 and 2008 were
included in this study. The samples consisted of 99 CJD+ and 75
CJD- cases, amounting to a total of 174 cases. Specific diagnosis of
CJD- cases included Alzheimer’s Disease (AD) (17), encephalitis (3),
meningoencephalitis (2), cortical dysplasia (1), cortical angiopathy
(1), angiitis with microinfarcts (1), infarct (1), cerebral vasculopathy
(1), Lewy body dementia (1), Lewy body variant of Alzheimer’s
disease (1), anoxic and Wernicke’s encephalopathies (1), meningeal
carcinomatosis (1), Alexander disease (1), leukoencephalopathy (1),
hippocampal sclerosis (1), frontotemporal dementia (1),
coccidioidomycosis meningoencephalitis (1), CNS lymphoma (1),
chronic meningoencephalitis (1), epilepsy or encephalopathy (1),
glioma (1), perivenous encephalomyelitis (1), CNS lymphoma (1),
military metastases (1), leptomeningeal lymphomatosis/leukemia
(1), mitochondrial encephalopathy (1), lymphoma (1), and non-CJD
dementia of uncertain diagnosis (29). The age at autopsy ranged
from 37–85 years for CJD+, and 47–84 years for CJD- cases. All
CSF samples were stored at 280uC until use. Human brain tissue
from the frontal cortex of CJD+ and age-matched cases of dementia
(CJD2) was obtained from the NPDPSC and stored at 280uC
(brain tissue and CSF samples are from different cases). Tissue
homogenates (10%) were prepared in lysis buffer and analyzed by
Western blotting following standard protocols.
Western blot and ELISA. Equal volume of CSF from CJD+
and CJD- cases was fractionated by SDS-PAGE and proteins
transferred to PVDF membranes were probed with anti-
transferrin antibody (Genetex Inc., Cat # GTX 21223) followed
by HRP-conjugated secondary antibody and visualization of
reactive bands with ECL (Amersham). Several procedural and
statistical precautions were taken to reduce error in comparing
multiple samples. Procedurally, a similar protocol was followed for
all Western blots, including exposure times. In addition, strips of
PVDF membrane representing specific molecular weights were
exposed to X-ray film simultaneously in large cassettes to obtain
similar exposure. Quantification of immunoreactive bands was
performed with UN-SCAN-IT software (version 6.1, Silk Scientific
Inc., Utah, USA) using three exposures from a single membrane
showing exponential increase in intensity. Statistically, results from
different Western blots were analyzed simultaneously in logistic
regression by treating these as clustered observations. The
statistical software Stata allows estimation of regression
coefficients after controlling for clustering to produce unbiased
standard errors. Two Stata procedures were used to do this: the
‘vce cluster’ option and svy option. Each logistic regression model
was first tested without adjustment for clustering and then tested
with each of the 2 clustering options. Both had the effect, in
general, of increasing standard errors and p-values for the
coefficient estimates as expected. However, the significance of
the coefficients of the biomarkers did not change; all their
coefficients remained significant at the p,.05 level. T-Tf (ELISA)
was estimated with Human Transferrin ELISA kit (Alpha
diagnostic international Inc., Cat # 1210) following the
manufacturer’s instructions. T-tau was determined by Human
Tau (total) ELISA Kit (Invitrogen, Camarillo, CA; KBH0042) as
directed by the manufacturer. Iron saturation of CSF Tf was
determined by radiolabeling with
59Fe followed by fractionation
on native gradient gels and autoradiography.
Statistical analysis
The following new biomarkers were evaluated for their
diagnostic accuracy: total transferrin by Western blot (T-Tf
(WB)) and ELISA (T-Tf (ELISA)) techniques, Tf-1, Tf-b2, and
iron saturation of Tf (
59Fe-Tf). Of these, T-Tf, Tf-1, and Tf-b2
offered greater promise, and were analyzed further either alone or
in combination with T-tau, a current biomarker that is
quantifiable and is superior to other CSF biomarkers used for
the diagnosis of sCJD [14,17,21,28].
A combination of univariate and multivariable statistical
methods were used to evaluate the relative diagnostic accuracy
of individual biomarkers. Since the biomarkers were expected to
evidence skewed distributions, nonparametric statistical proce-
dures were used as these are subject to fewer distributional
assumptions and provide less biased estimators when data are non-
normal. For relative analysis of individual biomarkers, the
nonparametric Mann-Whitney U test was used for focused
comparisons to test if the levels of new and current biomarkers
differ significantly between CJD+ and CJD-, and between CJD+
and AD cases. In addition, correlation analysis was performed
using Spearman’s rank correlation (r), which is also nonparamet-
ric. Finally, logistic regression, which makes no assumptions
regarding the distributional properties of data (e.g., non-normal)
[37] was used to parameterize the diagnostic accuracy of
biomarkers after controlling for age and duration (interval between
CSF collection and death). Because the data were clustered (four
sets of Western blots), logistic regression was conducted in Stata 10
with the option to correct standard errors for clustering. This
option is known to correct for underestimates of coefficient
standard errors, resulting in more conservative results.
Using logistic regression results, an analytic expression for the
risk of CJD was derived for each individual biomarker. Area under
the receiver operating characteristic (ROC) curve and the Aikake
Information Criterion (AIC) were obtained. A ROC curve
graphically shows the trade-offs between sensitivity and specificity
for different cut-offs used to discriminate between positive and
negative cases (i.e., CJD+ and CJD- cases). The area under the
ROC curve (AUC) can be understood as an estimate of the
probability that the biomarker being tested correctly ranks a CJD+
case higher than a CJD- case and, therefore, indexes the
discriminating power of the biomarker. The AIC is used to
compare different logistic regression models for different biomark-
ers (individually or in combination). A model with a relatively
lower AIC is considered superior due to its better fit to data and its
CSF Transferrin Is a Diagnostic Marker for sCJD
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and negative likelihood ratios (LR) were obtained given a baseline
sensitivity of 85%, which has precedence in the literature as a
reasonable cut-off level for biomarker comparison of Alzheimer’s
disease (AD) [38,39]. Positive LR is defined as sensitivity/
(1-specificity) and represents the increase in likelihood of a positive
test result if the disease is present compared to its being absent.
The negative LR is defined as (1-sensitivity)/specificity and
represents the decrease in likelihood of a negative test result if
the disease is present compared to it being absent. Positive and
negative LR, like specificity, depends on the chosen cut-off for
sensitivity (set at 85% in this study). Confidence intervals for
proportions were calculated according to the efficient-score
method and corrected for continuity [40]. Confidence intervals
for LRs were calculated as proposed in a previous report [41]. All
statistical tests were conducted at the 95% confidence level.
To identify an optimal combination of biomarkers, all two way
combinations of new and current biomarkers were also entered
into a logistic regression model with controls for age, duration, and
clustered data (as above). Combining new and current biomarker
T-tau was intended to take advantage of the differential
pathogenic mechanisms represented by these biomarkers. We
focused on two-way combinations for reasons of practicality.
However, a specific combination involving T-Tf and 14-3-3 could
not be evaluated because the readouts for 14-3-3 are not precisely
quantifiable, and this biomarker has demonstrated relatively low
specificity in previous studies [4–6].
All models were compared using three criteria: AUC, specificity,
and AIC [42]. Model comparisons were based on multiple indicators
while recognizing that specificity at a given level of sensitivity is a key
discriminating factor. Models with higher specificity were preferred.
The optimal biomarker or combination of biomarkers was expected
to ideally have the highest AUC and specificity, and the lowest AIC.
We also conducted power analysis as proposed in a previous report
[43]. We determined that the new biomarkers would possess a
discriminating power at least as good as T-tau; thus we based our
power calculation on the expected effect size of T-tau. From
previously published data on the power of T-Tau to discriminate
between CJD+ cases and other forms of dementia [44–46], we
c a l c u l a t e da ne x p e c t e ds t a n d a r d i z e dd i f f e r e n c eo fa tl e a s t1 . 7 .B a s e d
on this, our study yields an estimate of statistical power exceeding
0.99 for logistic regression as well as the Mann-Whitney U test.
Results
Tf levels are decreased in the CSF of sCJD cases
Evaluation of CSF Tf by Western blot (WB) reveals two distinct
bands representing Tf-1 and Tf-b2, the latter representing
deglycosylated Tf specific to the brain and CSF (Figure 1 A,
lanes 1–13). Total Tf (T-Tf (WB)) comprising of Tf-1 and Tf-b2
collectively, and individual subunits i.e. Tf-1 and Tf-b2 individ-
ually are decreased in the CSF of CJD+ relative to CJD- cases
(Figure 1 A, lanes 1–13). In contrast, brain homogenates show a
relative increase in T-Tf (WB), Tf-1, and Tf-b2 in CJD+ relative to
CJD- cases (Figure 1 A, lanes 14–17) (cut lanes were re-aligned for
comparison. Original blot is shown in Figure S1).
Quantitative comparison shows a decrease in CSF T-Tf (WB)
by 49% (z=8.73, p,.001) and an increase in brain T-Tf (WB) by
39% (z=2.76, p,.008) in CJD+ relative to CJD- cases (Figure 1
B, C). Comparison with AD cases shows a decrease in CSF T-Tf
(WB) by 39% in CJD+ relative to AD cases (z=4.92, p,.001)
(Figure 1 D). Estimation of CSF T-Tf by ELISA shows a decrease
of 30% in CJD+ relative to CJD- (z=6.53, p,.001), and 26%
relative to AD cases (z=3.02, p =.003) (Figure 2 A, B). The
difference in T-Tf measured by WB and ELISA methods is due to
optimization of the ELISA kit for serum Tf that lacks Tf-b2, and is
therefore less accurate in estimating brain T-Tf.
Comparison of individual subunits of Tf shows a decrease in
CSF Tf-1 by 35% (z=7.59, p,.001) and Tf-b2 by 61% (z=6.96,
p,.001) in CJD+ relative to CJD- samples (Figure 2 C, E), and a
decrease of 28% in Tf-1 (z=4.44, p,.001) and 59% in Tf-b2
(z=3.96, p,.001) relative to AD samples (Figure 2 D, F).
To compare the iron content of CSF Tf between CJD- and
CJD+ cases, first the iron saturation of CSF Tf from a relatively
normal CJD- case was determined by competing radiolabeled
59FeCl3 with decreasing concentrations of unlabeled FeCl3 and
fractionating
59Fe-Tf on a native gel for quantification (Figure S2
A, B). These results demonstrate that CSF Tf is not fully saturated
with iron (Figure S2 B). Subsequently, CSF samples representing
equal concentration of Tf (determined by ELISA) from CJD- and
CJD+ cases were incubated with equal counts of
59FeCl3 to
radiolabel Tf, dialyzed to remove free
59FeCl3, and fractionated on
a native gel (Figure S2 C). Quantification of
59Fe-Tf shows
equivalent saturation of CSF Tf from CJD-, CJD+, and AD
samples, indicating normal iron binding capacity CSF Tf
regardless of the underlying disease (Figure S2 D, E).
Biomarker levels and differential diagnostics of T-Tf as a
new biomarker for sCJD
Comparison of different biomarkers using Mann-Whitney U test
reveals that the new biomarkers T-Tf (WB), Tf-1, and Tf-b2 are
more sensitive differentiators of the CJD+ vs. CJD- groups in
comparison to the current biomarker T-tau (Table 1, Figures 2 A–
F and 3 A, B). Relative to T-tau, the absolute z-values for T-Tf
(WB) and Tf-1 are higher by at least 2 and 1 standard deviation
(SD) respectively (Table 1). Noting that differential diagnosis is
meaningful if the biomarker discrimination exceeds at least 2 SD,
the current use of T-tau biomarker provides equivalent diagnostic
accuracy as Tf-b2 (absolute z=6.37 and 6.96 respectively) and
Tf-1 (Dz=1.22), but significantly poorer than T-Tf (WB)
(Dz=2.36) (Table 1, Figures 2 A, C, E and 3 A). However, the
diagnostic accuracy of new biomarkers in differentiating CJD+
from AD does not yield comparable superiority over T-tau.
Rather, these biomarkers evidence similar discrimination. T-tau
has the highest z-value (z=25.17, p,.001), but its diagnostic
accuracy is equivalent to T-Tf, Tf-1 and Tf-b2( Dz=0.25, 0.73
and 1.21 respectively) (Table 1, Figure 1 D, Figures 2 B, D, F and
3 B). (In hypothesis testing, at a confidence level of 95%, any
difference in z-values greater than 1.96 is significant. Based on this
we reasoned that when z-values corresponding to individual
biomarkers differ by 2 or more, the biomarker with greater z-value
provides significantly greater discrimination at p=.05).
After controlling for patient age and duration, T-tau showed
significant correlation with duration in CJD+ (r=20.35, p,.001),
but not in CJD- cases (r=20.14, p=0.28). None of the new
biomarkers showed a significant correlation with duration in the
CJD+ or CJD- group. (Correlation of T-Tf (WB), Tf-1, and Tf-b2
in CJD+ group r=20.08, p=0.41; r=20.02, p=0.89; r=0.11,
p=0.29, respectively, and in CJD- group r=0.06, p=0.62;
r=0.01, p=0.96; r=0.06, p=0.64, respectively). These results
indicate that T-tau changes as sCJD progresses, while the new
biomarkers remain fairly stable in CJD+ and CJD- cases. None of
the biomarkers showed any correlation with age.
For comparative analysis of new and the current biomarker T-
tau, logistic regression analysis was performed. Only T-Tf (WB),
not T-Tf (ELISA) results are considered for reasons mentioned
above. When individual biomarkers are tested for their diagnostic
accuracy, the new biomarkers T-Tf (WB), Tf-1, and Tf-b2 are
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Tf-1 have significantly higher AUC (0.90 and 0.86 respectively)
than T-Tau (0.78). Tf-b2 also has a higher AUC (0.82) than T-tau,
but the difference is not significant. T-Tf (WB), Tf-1, and Tf-b2
yield significantly higher specificities of 71.6%, 65.7% and 64.2%
respectively, while T-tau shows a relatively low specificity of 48.4%
(see discussion below). Finally, the AICs for T-Tf (WB), Tf-1 and
Tf-b2 of 0.81, 0.96 and 1.03 respectively are all lower than the
AIC for T-Tau (1.23) (Table 2).
Among the new group of biomarkers, T-Tf (WB) has by far the
highest diagnostic accuracy relative to other individual biomark-
ers. Thus, T-Tf (WB) yields an AUC of 0.90 that is significantly
higher than corresponding values for other biomarkers with the
exception of Tf-1. The AIC associated with the logistic regression
Figure 1. Tf is decreased in the CSF and increased in the brain of CJD+ cases. (A) Immunoblotting for Tf shows reduced levels of Tf-1 and
Tf-b2 in the CSF of CJD+ relative to CJD- samples (lanes 1–13), and increased levels of both isoforms in the brain tissue of CJD+ relative to CJD-
samples (lanes 14–17) (55). (B–D) Box and whisker plots of T-Tf (WB) indicating the median, 25–75
th percentiles, and outliers. The top and bottom of
the ‘‘box’’ represent 75
th and 25
th percentile respectively. The ‘‘whiskers’’ represent the highest and lowest values. Outliers are values over 1.5 times
the interquartile range and are shown as circles away from the whiskers. Significance of biomarker differences between CJD- vs. CJD+ and AD vs.
CJD+ was calculated by the M-W test.
doi:10.1371/journal.pone.0016804.g001
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the specificity of T-Tf (WB) is significantly higher than that of
T-Tau and equivalent to that of Tf-1 and Tf-b2. However, T-Tf
(ELISA) does not have the same superior characteristics: the model
has a lower AUC (0.81), higher AIC (1.06), and poorer specificity
of 64.1% for reasons mentioned above.
Optimal prediction of sCJD
Past research shows that relative to any single biomarker, using
twobiomarkersincombination generallyenhances the predictionof
individuals likely to suffer from AD or sCJD [26,39]. Accordingly,
different combinations ofnewbiomarkersandT-tau wereevaluated
for their diagnostic accuracy. An optimal predictive model is
achieved when T-Tf (WB) is used in conjunction with T-Tau
(Figure 4). This combination yields an AUC of 0.93 (highest of all
combinations except for T-Tf (WB) where the difference is
insignificant), specificity of 87.5% (highest of all combinations),
and AIC of 0.7 (lowest of all combinations) (Figure 4, panel A,
Table 2). The addition of a second predictor variable makes the
modellessparsimoniouscomparedto models includingonly a single
Figure 2. Quantitative comparison of CSF Tf between CJD+ and other dementias by the M-W U test. (A–F) Box and whisker plots of
different biomarkers indicating the median, 25–75
th percentiles, and outliers as in Figure 1 B–D. Significance of biomarker differences between CJD-
vs. CJD+ and AD vs. CJD+ was calculated by the M–W test.
doi:10.1371/journal.pone.0016804.g002
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The fact that this model has the lowest AIC is therefore remarkable;
it indicates that the gain in fit to the data compared to other models
more than makes up for the decrease in parsimony. The superiority
of this combination over individual biomarkers is also clear in its
positive LR (6.8) which is significantly higher than all other
biomarkers, positive predictive value of 91%, and higher accuracy
of 86.2% relative to eachbiomarker individually (Table 2, Figure 4).
Finally, an equation was constructed based on logistic regression
analysis for the combination of T-Tf (WB) and T-tau such that the
sensitivity for CJD+ would approximate 85% [38,39]. To visualize
the discriminative power of T-Tf (WB) (y) and T-tau (x)
combination, this equation was plotted as a line in the scatter plot
of CJD, AD and other dementia cases (Figure 4, panel C).
Discussion
This report describes the accuracy of new biomarkers CSF T-Tf
(WB) including its two isoforms Tf-1 and Tf-b2 in identifying CJD+
from dementia of other causes. Using rigorous statistical modeling
and analysis of new and currently used biomarker T-tau, we
demonstrate that each of the new biomarkers is superior to T-tau,
and the combination of T-Tf (WB) and T-tau is more accurate in
identifying sCJD than the currently used combination of 14-3-3 and
T-tau. Below, we discuss distinctive features of the methodology
used for comparing new and current biomarkers, possible reasons
for high specificity of new biomarkers when used singly and
significant improvement in diagnostic accuracy when combined
with T-tau, and limitations of our study leading to directed avenues
in the identification of accurate CSF biomarker(s) for sCJD.
A rigorous statistical approach was used to examine the
significance (nonparametric M–W test), quantitative comparison
using uniform criteria (logistic regression), and sensitivity-specific-
ity interdependence (ROC) of different biomarkers. In contrast to
specific cut-off values for individual biomarkers, a preset sensitivity
of 85% was applied to all biomarkers to provide a common
quantitative baseline for comparison [38,39]. Though this method
has been used in the past for evaluation of biomarkers of AD [39],
Figure 3. Quantitative comparison of CSF T-tau between CJD+ and other dementias by the M–W U test. (A&B ) Box and whisker plots
of T-tau comparing CJD- vs. CJD+ and AD vs. CJD+ cases. Plot shows median, 25 to 75
th percentiles, and outliers as in Figures 1 and 2.
doi:10.1371/journal.pone.0016804.g003
Table 1. Individual biomarker performance by the Mann-Whitney U test.
Comparison test New Biomarkers Current Biomarker
T-Tf (WB) Tf-1 Tf-b2 T-Tf (ELISA) (mg/ml) T-tau (pg/ml)
CJD+ vs. CJD-
CJD+ median (n) 1257093 (99) 1017031 (87) 236243 (87) 26.46 (99) 11530.87 (95)
CJD- median (n) 2177893 (67) 1555881 (67) 606359 (67) 38.90 (64) 1266.97 (64)
M–W U Test
Z-statistic 8.73 7.59 6.96 6.53 26.37
p-value ,.001 ,.001 ,.001 ,.001 ,.001
CJD+ vs. AD only
CJD+ median (n) 1257093 (99) 1017031 (87) 236243 (87) 26.46 (99) 11530.87 (95)
AD median (n) 2009259 (17) 1413527 (17) 577539 (17) 36.89 (15) 876.40 (15)
M–W U Test
Z-statistic 4.92 4.44 3.96 3.02 25.17
p-value ,.001 ,.001 ,.001 0.003 ,.001
Note: The n ranges from 87 to 99 for biomarkers in the CJD+ group and from 64 to 67 for the CJD- group due to insufficient CSF volume. To ensure that varying n does
not introduce bias, an additional analysis was performed using cases with only non-missing values for all biomarkers (87 for CJD+ and 64 for CJD-). The results did not
differ noticeably from those reported above.
doi:10.1371/journal.pone.0016804.t001
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approach has been applied to compare different biomarkers of
sCJD. By this approach, the new biomarkers T-Tf (WB) and its
isoforms Tf-1 and Tf-b2 performed better than the current
biomarker T-tau in all parameters tested, i.e. sensitivity, specificity,
AUC, AIC, and accuracy. Comparison among the new biomark-
ers revealed that T-Tf (WB) is superior to Tf-1 and Tf-b2 in all of
the above parameters. This is probably because the ratio of Tf-1
and Tf-b2 varies between different cases, and the sum of these two
isoforms represented by T-Tf provides a more accurate estimate of
CSF Tf levels. The relative superiority of new biomarkers over T-
tau is probably due to their association with sCJD associated
pathology, in particular imbalance of brain iron homeostasis that
has emerged as a common feature of sCJD and prion disease
affected experimental models [32–36]. Diseased brains show a
phenotype of iron deficiency in the presence of increased brain
iron, suggesting sequestration of iron in biologically unavailable
complexes [32]. Reflection of this abnormality as altered levels of
CSF Tf therefore provides a disease associated biomarker, a
significant improvement over the surrogate biomarkers currently
used for the diagnosis of sCJD [3–8,11–18].
However, instead of the compensatory increase in CSF Tf in
response to brain iron deficiency as observed in cases of Restless
Leg Syndrome [47–49], CSF Tf is significantly reduced in sCJD
cases. A simplistic explanation for this observation is increased
uptake by the iron starved brain tissue, reducing levels of Tf in the
brain interstitial fluid and CSF that form a common compartment.
However, this is difficult to comprehend given the high metabolic
demand of brain cells for iron and the consequent tight regulation
of brain iron metabolism [50,51]. It is likely that accumulated iron
in PrP
Sc-protein complexes mitigates the signal for iron deficiency,
reducing Tf secretion [32,50,51]. We did not note a significant
difference in iron saturation of Tf between the two groups, ruling
out dysfunction of brain Tf as the underlying cause of brain iron
deficiency. It is surprising that age and duration had insignificant
effects on CSF T-Tf levels. This result is counter-intuitive given
the increase in brain Tf with disease progression [32,52]. Our
inability to detect a change in CSF Tf with duration may simply be
due to the late stage in the incubation period when CSF samples
were collected. A progressive decrease in CSF Tf may become
apparent if a single patient is followed over time.
Regardless of the underlying cause, the difference in CSF Tf
between CJD+ and CJD- cases is noted much before end-stage
disease, providing a useful pre-mortem diagnostic biomarker for
s C J D .W h e nc o m b i n e dw i t ht h es u r r o g a t eb i o m a r k e rT - t a u ,t h e
diagnostic accuracy of T-Tf (WB) and T-tau improves significantly,
and is superior to the reported accuracy of 14-3-3 and T-Tau
combination [16,17,27]. The dramatic improvement in diagnostic
accuracy of T-Tf and T-tau combination is probably due to the
distinct pathological processes represented by each biomarker; T-Tf
representing brain iron status, and T-tau the extent of neuronal death
[10]. Since brain iron deficiency is likely to induce neuronal death,
the two processes may be related, altering these biomarkers in unison
and therefore complementing their diagnostic capability.
Contrary to the norm, a specific cut-off value for T-Tf or T-tau was
not identified to calculate the specificity and sensitivity of these
biomarkers. For T-Tf we thought it pre-mature to decide on such a
value due to the limited sample size. For T-tau we did not use the
conventional cut-off of 1200 or 1300 pg/ml for three reasons: 1) a
consistent parameter was essential for comparing T-Tf and T-tau
singly or in combination, 2) majority of CJD- samples were collected
in the last month before death when T-tau is likely to be released into
the CSF from damaged neurons, and 3) inclusion of conditions such
as AD and brain inflammation that are associated with increased
levels of T-tau in the CSF [29–31]. The latter two conditions also
explain the low specificity of T-tau observed in our study relative to
published reports [17,26,27]. However, our samples represent a
typical CJD- group presenting for diagnostic testing, and partly
explain the wide variation in the specificity of T-tau reported by
different centers [15,25]. This is a major challenge since most
dementias associated with brain inflammation are curable if identified
early, and underscores the need for a diagnostic test of high specificity
to avoid misdiagnosis as sCJD for which there is currently no
treatment. It is encouraging that by combining T-Tf (WB) with T-tau
the specificity increases from 71.6% for T-Tf and 48.4% for T-tau to
87.5% for the T-Tf and T-tau combination, indicating that these
markers complement each other in their diagnostic capability.
In addition to its superior sensitivity and specificity, CSF Tf by
itself and in combination with T-tau offers several additional
advantages as a biomarker for sCJD: 1) CSF T-Tf reflects prion
disease associated brain iron imbalance and is therefore likely to be
more specific [32,53], 2) significant decrease in CSF Tf is noted
Table 2. Comparison of ‘new’ and ‘current’ biomarkers by logistic regression.
Statistic New Biomarkers (n) Current biomarker (n) New + Current
T-Tf (WB) (99) Tf-1 (87) Tf-b2 (87) T-Tf ELISA (99) T-tau (95) T-Tf (WB)+T-tau
Area under ROC (95%CI) 0.90 (0.85–0.94) 0.86 (0.80–0.92) 0.82 (0.76–0.89) 0.80 (0.73–0.88) 0.78 (0.71–0.85) 0.93 (0.89–0.97)
Sensitivity (95%CI) 85.9 (77.1–91.8) 85.1 (75.4–91.5) 85.1 (75.4–91.5) 85.9 (77.1–91.8) 85.3 (76.2–91.4) 85.3 (76.2–91.4)
Specificity (95%CI) 71.6 (59.1–81.7) 65.7 (53.0–76.6) 64.2 (51.5–75.3) 64.1 (51.0–75.4) 48.4 (35.9–61.2) 87.5 (76.3–94.1)
Positive LR (95%CI) 3.0 (2.1–4.5) 2.5 (1.8–3.5) 2.4 (1.7–3.3) 2.4 (1.7–3.3) 1.7 (1.3–2.1) 6.8 (3.5–13.1)
Negative LR (95%CI) 0.2 (0.1–0.3) 0.2 (0.1–0.4) 0.2 (0.1–0.4) 0.2 (0.1–0.4) 0.3 (0.2–0.5) 0.2 (0.1–0.3)
PPV (%) (95%CI) 81.7 (72.7–88.4) 76.3 (66.4–84.1) 75.5 (65.6–83.4) 78.7 (69.6–85.8) 71.1 (61.7–79.0) 91.0 (82.6–95.8)
NPV (%) (95%CI) 77.4 (64.7–86.7) 77.2 (63.8–86.8) 76.8 (63.3–86.6) 74.5 (60.7–84.9) 68.9 (53.2–81.4) 80.0 (68.4–88.3)
AIC 0.81 0.96 1.03 1.06 1.23 0.70
Accuracy 80.1 76.6 76 77.3 70.4 86.2
Note: Accuracy was defined as true positives + true negatives/total number tested.
Cut-off was chosen to achieve a sensitivity of ,85% [38,39].
Positive/negative LR results are robust to variations in prevalence rates between the study and overall population, and are provided in addition to PPV/NPV that are
highly dependent on the population tested.
doi:10.1371/journal.pone.0016804.t002
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for early diagnosis, 3) Tf is relatively resistant to limited
degradation by proteinase-K [32], ensuring consistent results even
in poorly preserved CSF samples, 4) since Tf-b2 displays
significant discriminatory power, blood contaminated CSF
samples can be used for testing, 5) levels of CSF Tf are in the
mg/ml range relative to 14-3-3 and T-tau that are in the pg/ml
range, allowing accurate detection from a small sample volume
without the necessary step of pre-absorption of albumin and
immunoglobulins, and 6) CSF T-Tf is quantifiable.
Inconclusion,reduced levels ofCSF Tfreinforcepreviousreports
indicating the association of brain iron dyshomeostasis with prion
disease pathology,andoffer promise asa pre-mortemdiagnostic test
for sCJD. Although alteration of CSF Tf in sCJD cases has been
described previously [53,54], the small number of cases analyzed
precludes direct comparison of these reports with our results.
Nevertheless, these studies provide confidence that CSF Tf holds
promise as biomarker of sCJD. Evaluation of additional CSF
samples from sCJD and other forms of prion disorders and
comparison with cases of rapid onset dementia will validate these
Figure 4. Potential of CSF T-Tf alone or in combination with T-tau as a diagnostic test for CJD+. (A&B ) ROC curve of T-Tf (WB) and T-Tf
(WB) in combination with T-tau. (C) Scatter graph shows separation of CJD+ from cases of AD and other dementias. Reference line shows the cut-off
equation derived to achieve a sensitivity of ,85%.
doi:10.1371/journal.pone.0016804.g004
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current automated procedures for quantifying serum Tf to CSF Tf
and provide a quick and sensitive pre-mortem diagnostic test for
sCJD and perhaps other human and animal prion disorders.
Supporting Information
Figure S1 Tf is increased in the brain tissue of CJD+
cases. Original immunoblot of brain Tf from CJD+ and CJD-
cases.
(TIF)
Figure S2 Iron saturation of CSF Tf is comparable in
CJD+ and CJD- cases. (A) Competition of
59FeCl3 with graded
concentrations of unlabeled FeCl3for binding to CSF Tf from a CJD-
case. (B) Standard curve demonstrating iron saturation of CSF Tf
from a CJD- case. (C) Level of
59Fe-Tf in the CSF of CJD+ and CJD-
c a s e si ss i mi l a r .( D&E )DifferencebetweenironsaturationofCSFTf
from CJD+, CJD-, and AD cases is not significant.
(TIF)
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